Disruption of normal blood flow to the heart, lung and brain is the leading cause of death and long-term adult disability in the western world (1) . Current approaches to acute therapy for ischemic stroke, coronary infarction, and pulmonary embolism require infusion of thrombolytic drugs, which need to be administered systemically or through a catheter placed within the obstructed vessel, usually in an acute care hospital setting (2-4). To be effective, patients must receive therapy within a few hours after onset of symptoms, and the doses of clot-lysing drugs that can be administered are limited by the potential risk of bleeding as active drug is free to distribute throughout the body. To overcome these limitations, we designed a thrombolytic delivery system that targets drugs selectively to sites of flow obstruction and concentrates active drug in these regions.
Stenotic and thrombosed blood vessels exhibit unique physical characteristics that distinguish them from normal vasculature in that fluid shear stress can increase locally by one to two orders of magnitude, from below approximately 70 dyne/cm 2 in normal vessels to greater than 1,000 dyne/cm 2 in highly constricted arteries (5) (6) (7) (8) . Normal circulating platelets are locally activated by high shear stress in these regions and rapidly adhere to the adjacent surface lining of the narrowed vessels (9) (10) (11) , which is a major contributing factor in development of vulnerable atherosclerotic plaques. Inspired by this natural physical mechanism of platelet targeting, we developed a therapeutic strategy that uses local high shear stress as a generic mechanism to target treatment to regions of blood vessels that are constricted by clots, stenosis or developmental abnormalities.
Our shear-activated nanotherapeutics (SA-NTs) are similar in size to natural platelets (1 to 5 μm in diameter); however, they are fabricated as aggregates of multiple smaller nanoparticles (NPs). The microscale aggregates remain intact when flowing in blood under physiological flow conditions, but break up into individual nanoscale components when exposed to high local shear stress. Because of their smaller size compared to the microscale aggregates, shear-dispersed NPs experience lower drag forces and hence, they adhere more efficiently to the surface of the adjacent blood vessel wall than the larger microaggregates ( fig. S1 ). The efficiency of this local adhesion can be further enhanced by coating the NPs with molecules that bind to endothelial cells or relevant targets, such as fibrin clots. In this manner, high concentrations of therapeutic agents can be concentrated locally at sites of vascular occlusion or embolism by immobilizing relevant drugs or enzymes on the NPs.
The SA-NTs were produced by spray-drying concentrated solutions of biocompatible, biodegradable, polylactic-co-glycolic acid (PLGA 50:50, MW 17kDa) to form micrometer-sized (3.8 ± 1.6 μm) aggregates composed of small (180 ± 70 nm) NPs (Fig. 1A) . Microaggregates of PLGA NPs are stable in aqueous solutions due to their hydrophobicity (12, 13) . But when exposed to mechanical forces that overcome the attractive forces holding the NPs together, such as hemodynamic shear stresses, the aggregates break apart (Fig. 1B) , much like a wet ball of sand disperses into individual grains when rubbed in one's hands.
To determine the shear-sensitivity of this NP deployment mechanism, we used a rheometer to apply controlled shear stresses in vitro to SA-NTs fabricated from NPs labeled with a fluorescent tag. We detected an 8-to 12-fold increase in the concentration of released NPs when the level of shear reached 100 dyne/cm 2 or higher (Fig. 1C ). This range of fluid shear stress is relevant in many vascular diseases. For example, computational fluid dynamics (CFD) modeling of flow within normal and stenotic human left coronary arteries based on ultrasound imaging (see Methods) (15, 16) revealed that the level of shear that induce NP release in vitro is similar to that generated by a 60% lumen obstruction (Fig. 1D ) whereas normal coronary vessels experience a 5-fold lower level of shear stress (~ 10 to 30 dyne/cm 2 ) that does not cause disruption of the SA-NTs.
To determine whether these SA-NTs can target agents selectively to stenotic regions under relevant hemodynamic flow conditions, we carried out studies in a three-dimensional (3D) microfluidic model of vascular narrowing fabricated from poly-dimethylsiloxane (PDMS) that was designed to mimic regions of living blood vessels with 90% lumen ob- (Fig. 2C ). Perfusion of SA-NTs (100 μg/ml in PBS) through these microfluidic devices resulted in a 16-fold increase in the release of free NPs, as measured in the solution flowing downstream of the obstruction compared to fluid flowing through unobstructed microfluidic channels of similar dimensions (Fig. 2D) . Moreover, fluorescence microscopic imaging confirmed that released NPs accumulated in endothelial cells cultured on the inner surface of the artificial microfluidic vessel just distal to the narrowed region whereas minimal uptake occurred in cells lining the channel prior to the constriction (Fig. 2E ).
To evaluate their functional potential, we fabricated SA-NTs containing fluorescent NPs coated with the FDA-approved thrombolytic drug, tissue plasminogen activator (tPA), using biotin-streptavidin chemistry (~5 × 10 5 tPA molecules/micro-aggregate) and tested their ability to dissolve blood clots. To examine the general utility of this shear-targeted nanotherapeutic approach (Fig. 3A) for removal of natural clots formed endogenously in vivo, we studied the effect of bolus injection of thrombolytic SA-NTs in an established mouse arterial thrombus model in which clot formation is triggered by injuring the vessel wall by direct exposure to ferric chloride (14) (15) (16) . Real-time, intravital, fluorescence microscopic studies confirmed that this treatment resulted in formation of large blood clots within minutes in injured mesenteric arteries (~100 μm diameter, normal wall shear stress ~30 dyne/cm 2 ) that occluded the diameter by more than 80% (Fig. 3 , B and C) and caused the local shear stress to increase by more than 15-fold (~450 dyne/cm 2 ) in these regions, as determined using an optical Doppler velocity meter (17) . Fluorescently-labeled tPA-carrying SA-NTs that were injected intravenously 8 min after chemical injury preferentially accumulated in the regions of clot formation, resulting in clear microscopic visualization of these lesions (Fig. 3B ). In addition, the locally deployed tPA-coated NPs induced progressive surface erosion of the thrombi, with complete clearance of occlusions occurring within 5 min after SA-NT injection (Fig. 3 , B and C, and movie S1). Continuous monitoring of unobstructed vessels for up to 15 min in the mesenteric bed revealed that intact microscale NP aggregates were present throughout the course of the study, indicating that circulation of the SA-NTs through the normal vasculature did not induce microaggregate disruption.
Importantly, shear-induced release of tPA-coated NPs from the SANTs reopened the obstructed mesenteric arteries and significantly delayed the time to vessel occlusion (29 ± 7 min with tPA-coated SA-NTs versus 12 ± 3 min with PBS), when vessel patency was monitored using intravenous injection of fluorescently-labeled platelets (~2.5% of total platelets) (Fig. 3 , C and D, and movie S2). In contrast, administration of the same dose of soluble tPA (free tPA), pre-dissociated tPA-NPs, or heat-fused tPA-NP microaggregates (which do not dissociate in high shear) did not delay thrombosis in this model (Fig. 3D ). Careful analysis of these results also revealed that even when a vessel is almost fully occluded, the microscale tPA-coated SA-NTs that bind to the surface of the clot can actively degrade and 'recanalize' the clot. Once this happens, flow and shear stress rapidly increase once again, and this feeds back to activate other tPA carrying SA-NTs, resulting in full clot removal ( Fig. 3C and movie S2 ). Taken together, these results provide proofof-principle that the SA-NT technology can be used to target clot-lysing agents to vascular occlusions, in addition to providing a way to image these lesions in real-time in situ.
To explore the potential value of the SA-NTs for treatment of lifethreatening embolic occlusions, we first tested their ability to dissolve experimentally induced fibrin clots in vitro. When pre-formed fibrin clots [250 ± 150 μm diameter produced by a water-in-oil emulsion technique (18)] were injected into microfluidic channels that contained constricted regions (80 μm high, 500 μm wide), the fibrin emboli lodged in the devices and partially obstructed flow in the channels (Fig. 4A) . When SA-NTs (100 μg/ml) carrying tPA (50 ng/ml) were infused at physiological flow rates through the clot-occluded microfluidic channels, the shear-dispersed fluorescent tPA-coated NPs accumulated at the surface of the artificial emboli, progressively dissolving the clots and reducing their size by one half within an hour of treatment ( Fig. 4A and  movie S3 ). In contrast, treatment with soluble tPA at the same concentration and flow conditions had negligible effects (<5% reduction in clot size) (Fig. 4B ).
Next, we tested the ability of this shear-activated tPA delivery system to reverse the effects of acute pulmonary embolism in an ex vivo whole mouse lung ventilation-perfusion model. A solution containing the pre-formed fibrin clots similar to those tested in the microfluidic channel were infused (0.1 ml/min for ~5 min; 1 × 10 3 clots/ml) through the pulmonary artery of the perfused lung. Occlusion of pulmonary blood vessels by multiple microemboli (Fig. 4C) caused the pulmonary artery pressure to increase by about 3-fold compared to its normal value (30 versus 8 mm Hg) (Fig. 4E) . We then perfused tPA-coated SA-NTs (100 μg/ml microscale aggregates containing NPs coated with 50 ng/ml tPA) through the pulmonary artery at a physiological flow rate (0.5 ml/min). Fluorescence microscopic analysis of tissue sections again confirmed that the tPA-NPs localized selectively at regions of vascular occlusion, producing a greater than 25-fold increase in accumulation of NPs at these sites, (Figs. 4, C and D) . Progressive lysis of the emboli by the tPA-NPs resulted in normalization of pulmonary artery pressure levels within 1 hour in this ex vivo model (Fig. 4E) . In contrast, perfusion of soluble tPA at the same concentration as that delivered on the injected tPA-coated NPs (50 ng/ml), or even at a ten times higher dose (500 ng/ml), failed to produce any significant response (Fig. 4F) . In fact, similar clot-lysing effects and hemodynamic changes were only observed when we administered a hundred times higher concentration of soluble tPA under identical flow conditions (Fig. 4F) ; this dose in mice (~2 mg/kg) is comparable to the therapeutic dose commonly used in humans (~1 mg/kg).
We then studied pulmonary embolism in living mice by infusing smaller preformed fluorescent fibrin clots (< 70 μm; ~1,000 clots) into the jugular vein of anesthetized mice, which accumulate in peripheral blood vessels in the lungs, as previously described (19) . SA-NTs coated with tPA were then infused either immediately after injection of emboli, or 30 min after they formed. Quantitation of the total area of fluorescent emboli visualized in the lungs using computerized image analysis confirmed that administration of the tPA-coated SA-NTs resulted in reduction of both total clot area and clot number by more than 60% when administered immediately after injection of emboli, and by more than 30% when infused one half hour after embolism (Fig. S2) .
To further examine the potential clinical relevance of our approach for treatment of life-threatening acute massive embolism, we infused a solution containing larger fibrin clots (150 ± 80 μm diameter; ~ 100/ injection), which accumulate in the main pulmonary arteries (19) much as they do in humans with pulmonary embolism, and the mice were then immediately infused with tPA-coated SA-NTs or with carrier fluid for 45 min. All control animals died within 1 hour after infusion of the clots (0% survival, n = 7, Fig. 4G ), whereas more than 80% of the treated mice survived (6 out of 7), and none of these SA-NTs-treated animals displayed any visible symptoms of respiratory distress.
The major potential advantage of the SA-NTs is their ability to enhance the safety of thrombolytic therapies by significantly reducing the drug dose required to be effective, as demonstrated by the ability of SANTs to clear pulmonary emboli when coated with a tPA dose ~1/100th that required for induction of similar clot-lysing effects by free tPA. SANTs also could help to minimize unwanted bleeding and neurotoxicity because they are cleared rapidly from the circulation (80% clearance in 5 min) ( fig. S3) , and due to their larger size, they should not diffuse as easily into injured tissues as free tPA does. Additionally, it is important to note that we have not observed any abnormal bleeding in mice during the extensive surgical manipulations that were involved in our pulmonary embolism and mesenteric artery occlusion models. Nevertheless, before advancing these SA-NTs toward clinical studies in the future, finer control over the size of the microscale aggregates and their pharmacokinetics will be required to ensure that they safely pass through all microvessels and are sustained in the circulation at effective levels (20) . Alternative methods to link tPA to NPs (e.g., direct conjugation by amine-carboxylate coupling or coupling based on biocompatible heterobifunctional PEG linkers; (21, 22) also will need to be explored to avoid immune responses associated with streptavidin/biotin conjugation and to increase conjugation efficiency as well as optimize tPA activity.
A previously described thrombo-prophylaxis strategy based on coupling plasminogen activators to carrier erythrocytes has shown promising results in preventing thrombosis in various animal models (23) (24) (25) . The SA-NTs described here can potentially be used to prevent formation of thrombi that partially occlude vascular flow, as occurs for example when a stable atherosclerotic plaque is transformed into a lifethreatening vulnerable plaque. However, in contrast to the erythrocyte delivery approach, which is limited to prevention of nascent clot formation, the shear-activated drug targeting strategy also offers the ability to treat and dissolve pre-existing fibrin clots, such as those found in patients with stroke and myocardial infarction as well as atherosclerosis. In this proof of principle study, we focused on SA-NTs coupled to a thrombolytic agent, tPA, which has high affinity for fibrin and thus, they were efficiently delivered to fibrin clots ( fig. S1 ). In addition, these tPAcoated SA-NTs were loaded with a fluorescent dye that also concentrated at vascular occlusion sites. In the future it should be possible to design and fabricate SA-NTs containing various drugs or imaging agents for localized treatment and real-time visualization in a variety of pathologies associated with vascular obstruction.
In summary, these findings illustrate how nanoengineering approaches inspired by pathophysiological mechanisms can be used to develop safer and more effective therapeutic strategies. In contrast to drug targeting mechanisms that focus on expression of distinct molecular species that can vary between tissues or patients, shear stress increases as a function of narrowing of the lumen diameter in all patients, regardless of the cause or location of obstruction, thus offering a robust and broadly applicable targeting strategy. With further refinement, the shearactivated drug targeting nanotechnology described here might, for example, allow the immediate administration of clot-busting drugs to patients suspected to have life-threatening clots in the brain, lung or other vital organs by emergency technicians or other care-givers, even before the patient has reached a hospital setting. Sequential intravital fluorescence microscopic images of a thrombus in a partially occluded mesenteric artery recorded over a 5 min period beginning after bolus injection of fluorescent tPA-coated SA-NTs (1 mg NPs; 50 ng tPA) 8 min after injury initiation (bar, 100 μm). Note that the NPs accumulate at the clot, first visualizing its location and then demonstrating clearance of the clot within 5 min after injection at the bottom (also see Supplementary Movie S1). (C) Sequence of intravital fluorescence microscopic images recorded over a 5 min period showing fluorescently-labeled platelets accumulated within a forming thrombus that partially occludes a mesenteric artery 8 min after injury. Thrombosis is then treated with injection of either tPA-carrying SA-NTs (50 ng tPA) (left) or PBS (right) (bar, 100 μm). Note that the clot on the left is greatly reduced in size within 5 min after SA-NTs injection (also Supplementary Movie S2), whereas the control vessel on the right fully occludes over the same time period. (D) Graph showing that a bolus injection of SANTs carrying 50 ng tPA (tPA-SA-NT) significantly delayed the time to full vascular occlusion in FeCl-injured vessels (***P < 0.0005), whereas administration of the same concentration of soluble tPA (free tPA), uncoated SA-NTs (bare SA-NT), tPAcoated NPs that were artificially dissociated from SA-NTs prior to injection (dispersed tPA-NPs), and heat-fused NP microaggregates with tPA coating that do not dissociate (fused SA-NT) did not produce any significant delay in thrombosis.
